Down-regulation of Cortical Beta-adrenoceptors by Chronic Treatment with Functional NMDA Antagonists

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1992 Jan 1

PMID 1312732

Citations 8

Authors

I A Paul

R Trullas

P Skolnick

G Nowak

Affiliations

Soon will be listed here.

Abstract

Down-regulation of cortical beta-adrenoceptors is observed in laboratory animals following chronic treatment with many clinically effective antidepressant therapies. [3H]Dihydroalprenolol (DHA) binding to cortical beta-adrenoceptors was examined in mice treated with the functional NMDA antagonists 1-aminocyclopropane-carboxylic acid (ACPC) and MK-801. ACPC and MK-801 reduced [3H]DHA binding by 19 (P less than 0.05) and 21% (P less than 0.05), respectively, while imipramine produced a 23% (P less than 0.05) reduction. No corresponding changes in the KD of [3H]DHA were observed. These findings are consistent with the observation that functional NMDA antagonists are active in animal models commonly used to evaluate antidepressants and may represent a novel approach to the treatment of depression.

Citing Articles

Molecular mechanism of noradrenaline during the stress-induced major depressive disorder.

Seki K, Yoshida S, Jaiswal M Neural Regen Res. 2018; 13(7):1159-1169.

PMID: 30028316 PMC: 6065220. DOI: 10.4103/1673-5374.235019.

New targets for rapid antidepressant action.

Machado-Vieira R, Henter I, Zarate Jr C Prog Neurobiol. 2016; 152:21-37.

PMID: 26724279 PMC: 4919246. DOI: 10.1016/j.pneurobio.2015.12.001.

NMDA Receptor Antagonists for Treatment of Depression.

Ates-Alagoz Z, Adejare A Pharmaceuticals (Basel). 2013; 6(4):480-99.

PMID: 24276119 PMC: 3816696. DOI: 10.3390/ph6040480.

Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders.

Quiroz J, Manji H Dialogues Clin Neurosci. 2011; 4(1):73-92.

PMID: 22034240 PMC: 3181673.

The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

Valentine G, Mason G, Gomez R, Fasula M, Watzl J, Pittman B Psychiatry Res. 2011; 191(2):122-7.

PMID: 21232924 PMC: 3061550. DOI: 10.1016/j.pscychresns.2010.10.009.

References

Kalivas P, Duffy P, Barrow J . Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J Pharmacol Exp Ther. 1989; 251(1):378-87. View

Jones S, Snell L, Johnson K . Phencyclidine selectively inhibits N-methyl-D-aspartate-induced hippocampal [3H]norepinephrine release. J Pharmacol Exp Ther. 1987; 240(2):492-7. View

Stockmeier C, Kellar K . Serotonin depletion unmasks serotonergic component of [3H]dihydroalprenolol binding in rat brain. Mol Pharmacol. 1989; 36(6):903-11. View

Willner P . Animal models of depression: an overview. Pharmacol Ther. 1990; 45(3):425-55. DOI: 10.1016/0163-7258(90)90076-e. View

Marvizon J, Lewin A, Skolnick P . 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem. 1989; 52(3):992-4. DOI: 10.1111/j.1471-4159.1989.tb02554.x. View

Pittaluga A, Raiteri M . Release-enhancing glycine-dependent presynaptic NMDA receptors exist on noradrenergic terminals of hippocampus. Eur J Pharmacol. 1990; 191(2):231-4. DOI: 10.1016/0014-2999(90)94153-o. View

Keith R, Mangano T, Meiners B, Stumpo R, Klika A, Patel J . HA-966 acts at a modulatory glycine site to inhibit N-methyl-D-aspartate-evoked neurotransmitter release. Eur J Pharmacol. 1989; 166(3):393-400. DOI: 10.1016/0014-2999(89)90351-8. View

Yee D, Pastuszko A, Nelson D, Wilson D . Effects of DL-2-amino-5-phosphonovalerate on metabolism of catecholamines in synaptosomes from rat brain. J Neurochem. 1989; 52(1):54-60. DOI: 10.1111/j.1471-4159.1989.tb10897.x. View

Paul I, Duncan G, Powell K, Mueller R, Hong J, Breese G . Regionally specific neural adaptation of beta adrenergic and 5-hydroxytryptamine2 receptors after antidepressant administration in the forced swim test and after chronic antidepressant drug treatment. J Pharmacol Exp Ther. 1988; 246(3):956-62. View

10.

Wong E, Kemp J, Priestley T, Knight A, Woodruff G, Iversen L . The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A. 1986; 83(18):7104-8. PMC: 386661. DOI: 10.1073/pnas.83.18.7104. View

11.

Ransom R, Deschenes N . NMDA-induced hippocampal [3H]norepinephrine release is modulated by glycine. Eur J Pharmacol. 1988; 156(1):149-55. DOI: 10.1016/0014-2999(88)90157-4. View

12.

Trullas R, Skolnick P . Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990; 185(1):1-10. DOI: 10.1016/0014-2999(90)90204-j. View

13.

Schmidt C, Taylor V . Release of [3H]norepinephrine from rat hippocampal slices by N-methyl-D-aspartate: comparison of the inhibitory effects of Mg2+ and MK-801. Eur J Pharmacol. 1988; 156(1):111-20. DOI: 10.1016/0014-2999(88)90153-7. View